Balixafortide

Spexis AG / Key word(s): Miscellaneous 17-Apr-2024 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 17, 2024 Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera The Western District Court of the Canton Basel-Landschaft has granted Spexis’ request to extend its provisional moratorium by an additional 4 months. Spexis received the second of three potential payments as part of an asset purchase agreement announced on Jan 15, 2024 totaling CHF 2 million. Santhera Pharmaceuticals Holding AG (Pratteln, Switzerland) has terminated the license agreement relating to lonodelestat, Spexis’ inhaled neutrophil elastase inhibitor, as part of its portfolio review and announced focus on its lead asset vamorolone. Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that its request to extend its provisional moratorium has been granted for an additional four months by the Western District Court of the Canton Basel-Landschaft. This request was made as part of Spexis’ efforts to partner or divest non-core programs and assets and raise additional capital in order to eventually emerge from moratorium. In addition, Spexis sold all rights to a preclinical program of macrocycle antibiotics developed by Spexis from a novel class (outer membrane protein targeting antibiotics, or “OMPTAs”) targeting Gram-negative bacteria, including multidrug-resistant strains, under an asset purchase agreement to Basilea Pharmaceutica International Ltd, Allschwil. The transaction was first reported on 15 January 2024 and further reported on 8 February 2024 upon closing. In the meantime, Basilea has made the second of three total potential payments to Spexis. This payment related to the completion of transfer of the asset to Basilea. Finally, Spexis announces that Santhera Pharmaceuticals Holding AG (Pratteln, Switzerland) has terminated the February 2018 agreement wherein Spexis (formerly Polyphor) out-licensed worldwide rights of lonodelestat, its novel, inhaled neutrophil elastase inhibitor, to Santhera. Importantly, the decision to terminate the license was taken in light of Santhera’s portfolio prioritization, and not as a result of any safety or efficacy data having arisen from the Phase 1a or Phase 1b studies undertaken on lonodelestat during the term of the license. All rights to lonodelestat and all data generated by Santhera on lonodelestat during the term of the license shall revert to Spexis during a brief transition period. Jeff Wager, MD, Chairman & CEO of Spexis, said: “These three events represent significant progress in the implementation of Spexis' moratorium plan, and we continue to pursue the goal of ultimately emerging from moratorium status. In addition, the reversion of lonodelestat rights to Spexis also strengthens one of our core rare disease aereas – that of niche respiratory conditions – wherein Spexis already has significant assets and experience. We thank Santhera for the progress they made with lonodelestat as a licensee, and based upon this progress, we plan to announce further, innovative development plans as soon as practicable. We continue to have great confidence in the novelty of our macrocycle technology as a drug discovery platform to ultimately address significant unmet medical needs in rare disease and oncology.” About Spexis Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com. About Spexis’ Macrocycle Platforms Spexis possesses what we regard as some of the most distinct, highly diverse and very well characterized macrocycle libraries in the world, together with deep data on same, developed over the course of more than 25 years of research and development and significant investment. These include PEMFinder™, which is comprised of peptidomimetic macrocycles, and MACROFinder™, which are small molecule macrocycles. Each have distinct applications depending on the targets in question, which can be both extracelluar and intracellular targets. In addition to generating the specific OMPTA candidates described in this press release, these platforms have generated multiple other drug candidates in the Spexis pipeline, including murepavidin, balixafortide, lonodelestat and others. About Lonodelestat Lonodelestat is a highly potent and selective peptide inhibitor of human neutrophil elastase (hNE). Neutrophil elastase is an enzyme associated with tissue inflammation, leading to degradation of the lung tissue in several acute and chronic pulmonary diseases. In preclinical studies, lonodelestat was effective in animal models of neutrophil activation in lung tissue and of acute lung injury (ALI) [1, 2]. Currently available clinical data demonstrated that single and multiple doses (Phase 1b) of lonodelestat when administered by inhalation via an optimized eFlow® nebulizer (PARI Pharma GmbH) can lead to high drug concentrations within the lung, resulting in inhibition of hNE in sputum of patients, an enzyme associated with lung tissue inflammation [3]. The Phase 1b study further confirmed the tolerability of lonodelestat after treatment of up to four weeks in patients with CF. Lonodelestat may also show therapeutic benefit for a range of neutrophilic pulmonary diseases with high medical need such as non-CF bronchiectasis (NCFB), alpha-1 antitrypsin deficiency (AATD), chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS) or primary ciliary dyskinesia (PCD), amongst many others. Lonodelestat currently has EU orphan drug designations (ODD) for the treatment of CF as well as for AATD and PCD in both EU and US. Both Spexis and Santhera acknowledges the support of the Cystic Fibrosis Foundation (CFF) by providing funding for the conduct of the Phase 1a and 1b safety trials with lonodelestat. For further information please contact: Disclaimer This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release can be downloaded from www.spexisbio.com References

Spexis announces closing of sale of preclinical antibiotics program to Basilea Spexis AG / Key word(s): Miscellaneous 08-Feb-2024 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 8, 2024 Spexis announces closing of sale of preclinical antibiotics program to Basilea Basilea to pay up to CHF 2 million for a preclinical program with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains Transaction is part of Spexis’ efforts to partner or divest non-core programs and assets as the company works through its moratorium status Transaction was subject to certain closing conditions, which now have been met and which will commence payments from Basilea to Spexis Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that it has closed its asset purchase agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) wherein Basilea has now formally become the owner of a preclinical program of antibiotics developed by Spexis from a novel class targeting Gram-negative bacteria, including multidrug-resistant strains.1 The transaction was subject to the approval by the Western District Court of the Canton Basel-Landschaft, which has now been obtained. As part of the completed transaction, Basilea has acquired all program compounds, including intellectual property, and is paying Spexis up to a total of CHF 2 million, which consists of an upfront payment which was now received at closing, a payment related to the near-term transfer of the assets to Basilea, which is expected by the end of February and a potential final milestone payment related to the availability of near-term external funding for the further development of the program. In addition, Basilea has assumed the rights and obligations of Spexis related to the program, including potential low single-digit percentage royalties on sales, under licensing agreements. The assets sold to Basilea are macrocyclic antibiotics developed within Spexis’ Outer Membrane Protein Targeting Antibiotics (OMPTA) program which selectively disrupt the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. This results in a loss of the integrity of the outer cell membrane, intracellular accumulation of lipopolysaccharides and killing of the bacteria. Activity has been shown in vitro and in vivo against Enterobacteriaceae such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy. The program was funded in part by CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)2, a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. Jeff Wager, MD, Chairman & CEO of Spexis, said: “We are very pleased to have finalized this transaction with Basilea as it underscores the power of our macrocycle platform as a drug discovery platform and its potential to generate products that can address significant unmet medical needs. From a corporate strategy perspective, this transaction is part of Spexis’ efforts to partner or divest non-core programs and assets as the company works towards exiting its moratorium status and will generate funds and streamline focus which we can utilize towards advancing our core programs in rare disease and oncology. ” About multidrug-resistant Gram-negative bacteria Infections by multidrug-resistant Gram-negative bacteria (GNB) are a major challenge for healthcare professionals. Due to an additional outer cell membrane compared to Gram-positive bacteria, it is more difficult for antibiotics to get into the cell. In addition, this outer membrane carries lipopolysaccharides/endotoxins which induce inflammation and play an important amplifying role in the pathogenesis of infections by GNB and are therefore considered an important virulence factor. Moreover, GNB can acquire resistance to several classes of antibiotics such as carbapenems, fluoroquinolones, tetracyclines and earlier-generation cephalosporins, making infections with GNBs particularly difficult to treat. In 2017, the World Health Organization published a list of 12 classes of priority bacterial pathogens that pose the greatest threat to human health, of which nine classes are Gram-negative.3 About Spexis Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com. About Spexis’ Macrocycle Platforms Spexis possesses what we regard as some of the most distinct, highly diverse and very well characterized macrocycle libraries in the world, together with deep data on same, developed over the course of more than 25 years of research and development and significant investment. These include PEMFinder™, which is comprised of peptidomimetic macrocycles, and MACROFinder™, which are small molecule macrocycles. Each have distinct applications depending on the targets in question, which can be both extracelluar and intracellular targets. In addition to generating the specific OMPTA candidates described in this press release, these platforms have generated multiple other drug candidates in the Spexis pipeline, including murepavidin, balixafortide, lonodelestat and others. For further information please contact: For Investors: Stephen Jasper Managing Director Gilmartin Group stephen@gilmartinir.com For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 9256 feldhaus@feldhaus-partner.ch Disclaimer This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release can be downloaded from www.spexisbio.com References M. Schuster, E. Brabet, K. K. Oi et al. Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae. Science Advances 2023 (9), eadg3683 Research reported in this press release is supported by CARB-X. CARB-X’s funding for this project is provided in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority under agreement number 75A50122C00028; and by awards from Wellcome (WT224842), and Germany’s Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (Accessed: January 11th, 2024) End of Inside Information Language:EnglishCompany:Spexis AGHegenheimermattweg 1254123 AllschwilSwitzerlandPhone:+41 61 567 1600Fax:+41 61 567 1601E-mail:info@spexisbio.comInternet:www.spexisbio.comISIN:CH0106213793Valor:SPEXListed:SIX Swiss ExchangeEQS News ID:1832895 End of AnnouncementEQS News Service Spexis AG / Key word(s): Miscellaneous 08-Feb-2024 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 8, 2024 Spexis announces closing of sale of preclinical antibiotics program to Basilea Basilea to pay up to CHF 2 million for a preclinical program with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains Transaction is part of Spexis’ efforts to partner or divest non-core programs and assets as the company works through its moratorium status Transaction was subject to certain closing conditions, which now have been met and which will commence payments from Basilea to Spexis Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that it has closed its asset purchase agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) wherein Basilea has now formally become the owner of a preclinical program of antibiotics developed by Spexis from a novel class targeting Gram-negative bacteria, including multidrug-resistant strains.1 The transaction was subject to the approval by the Western District Court of the Canton Basel-Landschaft, which has now been obtained. As part of the completed transaction, Basilea has acquired all program compounds, including intellectual property, and is paying Spexis up to a total of CHF 2 million, which consists of an upfront payment which was now received at closing, a payment related to the near-term transfer of the assets to Basilea, which is expected by the end of February and a potential final milestone payment related to the availability of near-term external funding for the further development of the program. In addition, Basilea has assumed the rights and obligations of Spexis related to the program, including potential low single-digit percentage royalties on sales, under licensing agreements. The assets sold to Basilea are macrocyclic antibiotics developed within Spexis’ Outer Membrane Protein Targeting Antibiotics (OMPTA) program which selectively disrupt the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. This results in a loss of the integrity of the outer cell membrane, intracellular accumulation of lipopolysaccharides and killing of the bacteria. Activity has been shown in vitro and in vivo against Enterobacteriaceae such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy. The program was funded in part by CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)2, a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. Jeff Wager, MD, Chairman & CEO of Spexis, said: “We are very pleased to have finalized this transaction with Basilea as it underscores the power of our macrocycle platform as a drug discovery platform and its potential to generate products that can address significant unmet medical needs. From a corporate strategy perspective, this transaction is part of Spexis’ efforts to partner or divest non-core programs and assets as the company works towards exiting its moratorium status and will generate funds and streamline focus which we can utilize towards advancing our core programs in rare disease and oncology. ” About multidrug-resistant Gram-negative bacteria Infections by multidrug-resistant Gram-negative bacteria (GNB) are a major challenge for healthcare professionals. Due to an additional outer cell membrane compared to Gram-positive bacteria, it is more difficult for antibiotics to get into the cell. In addition, this outer membrane carries lipopolysaccharides/endotoxins which induce inflammation and play an important amplifying role in the pathogenesis of infections by GNB and are therefore considered an important virulence factor. Moreover, GNB can acquire resistance to several classes of antibiotics such as carbapenems, fluoroquinolones, tetracyclines and earlier-generation cephalosporins, making infections with GNBs particularly difficult to treat. In 2017, the World Health Organization published a list of 12 classes of priority bacterial pathogens that pose the greatest threat to human health, of which nine classes are Gram-negative.3 About Spexis Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com. About Spexis’ Macrocycle Platforms Spexis possesses what we regard as some of the most distinct, highly diverse and very well characterized macrocycle libraries in the world, together with deep data on same, developed over the course of more than 25 years of research and development and significant investment. These include PEMFinder™, which is comprised of peptidomimetic macrocycles, and MACROFinder™, which are small molecule macrocycles. Each have distinct applications depending on the targets in question, which can be both extracelluar and intracellular targets. In addition to generating the specific OMPTA candidates described in this press release, these platforms have generated multiple other drug candidates in the Spexis pipeline, including murepavidin, balixafortide, lonodelestat and others. For further information please contact: For Investors: Stephen Jasper Managing Director Gilmartin Group stephen@gilmartinir.com For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 9256 feldhaus@feldhaus-partner.ch Disclaimer This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release can be downloaded from www.spexisbio.com References M. Schuster, E. Brabet, K. K. Oi et al. Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae. Science Advances 2023 (9), eadg3683 Research reported in this press release is supported by CARB-X. CARB-X’s funding for this project is provided in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority under agreement number 75A50122C00028; and by awards from Wellcome (WT224842), and Germany’s Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (Accessed: January 11th, 2024) End of Inside Information Spexis AG / Key word(s): Miscellaneous 08-Feb-2024 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 8, 2024 Spexis announces closing of sale of preclinical antibiotics program to Basilea Basilea to pay up to CHF 2 million for a preclinical program with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains Transaction is part of Spexis’ efforts to partner or divest non-core programs and assets as the company works through its moratorium status Transaction was subject to certain closing conditions, which now have been met and which will commence payments from Basilea to Spexis Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that it has closed its asset purchase agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) wherein Basilea has now formally become the owner of a preclinical program of antibiotics developed by Spexis from a novel class targeting Gram-negative bacteria, including multidrug-resistant strains.1 The transaction was subject to the approval by the Western District Court of the Canton Basel-Landschaft, which has now been obtained. As part of the completed transaction, Basilea has acquired all program compounds, including intellectual property, and is paying Spexis up to a total of CHF 2 million, which consists of an upfront payment which was now received at closing, a payment related to the near-term transfer of the assets to Basilea, which is expected by the end of February and a potential final milestone payment related to the availability of near-term external funding for the further development of the program. In addition, Basilea has assumed the rights and obligations of Spexis related to the program, including potential low single-digit percentage royalties on sales, under licensing agreements. The assets sold to Basilea are macrocyclic antibiotics developed within Spexis’ Outer Membrane Protein Targeting Antibiotics (OMPTA) program which selectively disrupt the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. This results in a loss of the integrity of the outer cell membrane, intracellular accumulation of lipopolysaccharides and killing of the bacteria. Activity has been shown in vitro and in vivo against Enterobacteriaceae such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy. The program was funded in part by CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)2, a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. Jeff Wager, MD, Chairman & CEO of Spexis, said: “We are very pleased to have finalized this transaction with Basilea as it underscores the power of our macrocycle platform as a drug discovery platform and its potential to generate products that can address significant unmet medical needs. From a corporate strategy perspective, this transaction is part of Spexis’ efforts to partner or divest non-core programs and assets as the company works towards exiting its moratorium status and will generate funds and streamline focus which we can utilize towards advancing our core programs in rare disease and oncology. ” About multidrug-resistant Gram-negative bacteria Infections by multidrug-resistant Gram-negative bacteria (GNB) are a major challenge for healthcare professionals. Due to an additional outer cell membrane compared to Gram-positive bacteria, it is more difficult for antibiotics to get into the cell. In addition, this outer membrane carries lipopolysaccharides/endotoxins which induce inflammation and play an important amplifying role in the pathogenesis of infections by GNB and are therefore considered an important virulence factor. Moreover, GNB can acquire resistance to several classes of antibiotics such as carbapenems, fluoroquinolones, tetracyclines and earlier-generation cephalosporins, making infections with GNBs particularly difficult to treat. In 2017, the World Health Organization published a list of 12 classes of priority bacterial pathogens that pose the greatest threat to human health, of which nine classes are Gram-negative.3 About Spexis Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com. About Spexis’ Macrocycle Platforms Spexis possesses what we regard as some of the most distinct, highly diverse and very well characterized macrocycle libraries in the world, together with deep data on same, developed over the course of more than 25 years of research and development and significant investment. These include PEMFinder™, which is comprised of peptidomimetic macrocycles, and MACROFinder™, which are small molecule macrocycles. Each have distinct applications depending on the targets in question, which can be both extracelluar and intracellular targets. In addition to generating the specific OMPTA candidates described in this press release, these platforms have generated multiple other drug candidates in the Spexis pipeline, including murepavidin, balixafortide, lonodelestat and others. For further information please contact: For Investors: Stephen Jasper Managing Director Gilmartin Group stephen@gilmartinir.com For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 9256 feldhaus@feldhaus-partner.ch Disclaimer This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release can be downloaded from www.spexisbio.com References M. Schuster, E. Brabet, K. K. Oi et al. Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae. Science Advances 2023 (9), eadg3683 Research reported in this press release is supported by CARB-X. CARB-X’s funding for this project is provided in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority under agreement number 75A50122C00028; and by awards from Wellcome (WT224842), and Germany’s Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (Accessed: January 11th, 2024) End of Inside Information Spexis AG / Key word(s): Miscellaneous 08-Feb-2024 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 8, 2024 Spexis announces closing of sale of preclinical antibiotics program to Basilea Basilea to pay up to CHF 2 million for a preclinical program with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains Transaction is part of Spexis’ efforts to partner or divest non-core programs and assets as the company works through its moratorium status Transaction was subject to certain closing conditions, which now have been met and which will commence payments from Basilea to Spexis Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that it has closed its asset purchase agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) wherein Basilea has now formally become the owner of a preclinical program of antibiotics developed by Spexis from a novel class targeting Gram-negative bacteria, including multidrug-resistant strains.1 The transaction was subject to the approval by the Western District Court of the Canton Basel-Landschaft, which has now been obtained. As part of the completed transaction, Basilea has acquired all program compounds, including intellectual property, and is paying Spexis up to a total of CHF 2 million, which consists of an upfront payment which was now received at closing, a payment related to the near-term transfer of the assets to Basilea, which is expected by the end of February and a potential final milestone payment related to the availability of near-term external funding for the further development of the program. In addition, Basilea has assumed the rights and obligations of Spexis related to the program, including potential low single-digit percentage royalties on sales, under licensing agreements. The assets sold to Basilea are macrocyclic antibiotics developed within Spexis’ Outer Membrane Protein Targeting Antibiotics (OMPTA) program which selectively disrupt the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. This results in a loss of the integrity of the outer cell membrane, intracellular accumulation of lipopolysaccharides and killing of the bacteria. Activity has been shown in vitro and in vivo against Enterobacteriaceae such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy. The program was funded in part by CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)2, a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. Jeff Wager, MD, Chairman & CEO of Spexis, said: “We are very pleased to have finalized this transaction with Basilea as it underscores the power of our macrocycle platform as a drug discovery platform and its potential to generate products that can address significant unmet medical needs. From a corporate strategy perspective, this transaction is part of Spexis’ efforts to partner or divest non-core programs and assets as the company works towards exiting its moratorium status and will generate funds and streamline focus which we can utilize towards advancing our core programs in rare disease and oncology. ” About multidrug-resistant Gram-negative bacteria Infections by multidrug-resistant Gram-negative bacteria (GNB) are a major challenge for healthcare professionals. Due to an additional outer cell membrane compared to Gram-positive bacteria, it is more difficult for antibiotics to get into the cell. In addition, this outer membrane carries lipopolysaccharides/endotoxins which induce inflammation and play an important amplifying role in the pathogenesis of infections by GNB and are therefore considered an important virulence factor. Moreover, GNB can acquire resistance to several classes of antibiotics such as carbapenems, fluoroquinolones, tetracyclines and earlier-generation cephalosporins, making infections with GNBs particularly difficult to treat. In 2017, the World Health Organization published a list of 12 classes of priority bacterial pathogens that pose the greatest threat to human health, of which nine classes are Gram-negative.3 About Spexis Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com. About Spexis’ Macrocycle Platforms Spexis possesses what we regard as some of the most distinct, highly diverse and very well characterized macrocycle libraries in the world, together with deep data on same, developed over the course of more than 25 years of research and development and significant investment. These include PEMFinder™, which is comprised of peptidomimetic macrocycles, and MACROFinder™, which are small molecule macrocycles. Each have distinct applications depending on the targets in question, which can be both extracelluar and intracellular targets. In addition to generating the specific OMPTA candidates described in this press release, these platforms have generated multiple other drug candidates in the Spexis pipeline, including murepavidin, balixafortide, lonodelestat and others. For further information please contact: For Investors: Stephen Jasper Managing Director Gilmartin Group stephen@gilmartinir.com For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 9256 feldhaus@feldhaus-partner.ch Disclaimer This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release can be downloaded from www.spexisbio.com References M. Schuster, E. Brabet, K. K. Oi et al. Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae. Science Advances 2023 (9), eadg3683 Research reported in this press release is supported by CARB-X. CARB-X’s funding for this project is provided in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority under agreement number 75A50122C00028; and by awards from Wellcome (WT224842), and Germany’s Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (Accessed: January 11th, 2024) End of Inside Information Spexis AG / Key word(s): Miscellaneous 08-Feb-2024 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 8, 2024 Spexis announces closing of sale of preclinical antibiotics program to Basilea Basilea to pay up to CHF 2 million for a preclinical program with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains Transaction is part of Spexis’ efforts to partner or divest non-core programs and assets as the company works through its moratorium status Transaction was subject to certain closing conditions, which now have been met and which will commence payments from Basilea to Spexis Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that it has closed its asset purchase agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) wherein Basilea has now formally become the owner of a preclinical program of antibiotics developed by Spexis from a novel class targeting Gram-negative bacteria, including multidrug-resistant strains.1 The transaction was subject to the approval by the Western District Court of the Canton Basel-Landschaft, which has now been obtained. As part of the completed transaction, Basilea has acquired all program compounds, including intellectual property, and is paying Spexis up to a total of CHF 2 million, which consists of an upfront payment which was now received at closing, a payment related to the near-term transfer of the assets to Basilea, which is expected by the end of February and a potential final milestone payment related to the availability of near-term external funding for the further development of the program. In addition, Basilea has assumed the rights and obligations of Spexis related to the program, including potential low single-digit percentage royalties on sales, under licensing agreements. The assets sold to Basilea are macrocyclic antibiotics developed within Spexis’ Outer Membrane Protein Targeting Antibiotics (OMPTA) program which selectively disrupt the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. This results in a loss of the integrity of the outer cell membrane, intracellular accumulation of lipopolysaccharides and killing of the bacteria. Activity has been shown in vitro and in vivo against Enterobacteriaceae such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy. The program was funded in part by CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)2, a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. Jeff Wager, MD, Chairman & CEO of Spexis, said: “We are very pleased to have finalized this transaction with Basilea as it underscores the power of our macrocycle platform as a drug discovery platform and its potential to generate products that can address significant unmet medical needs. From a corporate strategy perspective, this transaction is part of Spexis’ efforts to partner or divest non-core programs and assets as the company works towards exiting its moratorium status and will generate funds and streamline focus which we can utilize towards advancing our core programs in rare disease and oncology. ” About multidrug-resistant Gram-negative bacteria Infections by multidrug-resistant Gram-negative bacteria (GNB) are a major challenge for healthcare professionals. Due to an additional outer cell membrane compared to Gram-positive bacteria, it is more difficult for antibiotics to get into the cell. In addition, this outer membrane carries lipopolysaccharides/endotoxins which induce inflammation and play an important amplifying role in the pathogenesis of infections by GNB and are therefore considered an important virulence factor. Moreover, GNB can acquire resistance to several classes of antibiotics such as carbapenems, fluoroquinolones, tetracyclines and earlier-generation cephalosporins, making infections with GNBs particularly difficult to treat. In 2017, the World Health Organization published a list of 12 classes of priority bacterial pathogens that pose the greatest threat to human health, of which nine classes are Gram-negative.3 About Spexis Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com. About Spexis’ Macrocycle Platforms Spexis possesses what we regard as some of the most distinct, highly diverse and very well characterized macrocycle libraries in the world, together with deep data on same, developed over the course of more than 25 years of research and development and significant investment. These include PEMFinder™, which is comprised of peptidomimetic macrocycles, and MACROFinder™, which are small molecule macrocycles. Each have distinct applications depending on the targets in question, which can be both extracelluar and intracellular targets. In addition to generating the specific OMPTA candidates described in this press release, these platforms have generated multiple other drug candidates in the Spexis pipeline, including murepavidin, balixafortide, lonodelestat and others. For further information please contact: For Investors: Stephen Jasper Managing Director Gilmartin Group stephen@gilmartinir.com For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 9256 feldhaus@feldhaus-partner.ch Disclaimer This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release can be downloaded from www.spexisbio.com References M. Schuster, E. Brabet, K. K. Oi et al. Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae. Science Advances 2023 (9), eadg3683 Research reported in this press release is supported by CARB-X. CARB-X’s funding for this project is provided in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority under agreement number 75A50122C00028; and by awards from Wellcome (WT224842), and Germany’s Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (Accessed: January 11th, 2024) End of Inside Information Spexis AG / Key word(s): Miscellaneous 08-Feb-2024 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. 08-Feb-2024 / 07:15 CET/CEST Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 8, 2024 Spexis announces closing of sale of preclinical antibiotics program to Basilea Basilea to pay up to CHF 2 million for a preclinical program with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains Transaction is part of Spexis’ efforts to partner or divest non-core programs and assets as the company works through its moratorium status Transaction was subject to certain closing conditions, which now have been met and which will commence payments from Basilea to Spexis Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that it has closed its asset purchase agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) wherein Basilea has now formally become the owner of a preclinical program of antibiotics developed by Spexis from a novel class targeting Gram-negative bacteria, including multidrug-resistant strains.1 The transaction was subject to the approval by the Western District Court of the Canton Basel-Landschaft, which has now been obtained. As part of the completed transaction, Basilea has acquired all program compounds, including intellectual property, and is paying Spexis up to a total of CHF 2 million, which consists of an upfront payment which was now received at closing, a payment related to the near-term transfer of the assets to Basilea, which is expected by the end of February and a potential final milestone payment related to the availability of near-term external funding for the further development of the program. In addition, Basilea has assumed the rights and obligations of Spexis related to the program, including potential low single-digit percentage royalties on sales, under licensing agreements. The assets sold to Basilea are macrocyclic antibiotics developed within Spexis’ Outer Membrane Protein Targeting Antibiotics (OMPTA) program which selectively disrupt the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. This results in a loss of the integrity of the outer cell membrane, intracellular accumulation of lipopolysaccharides and killing of the bacteria. Activity has been shown in vitro and in vivo against Enterobacteriaceae such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy. The program was funded in part by CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)2, a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. Jeff Wager, MD, Chairman & CEO of Spexis, said: “We are very pleased to have finalized this transaction with Basilea as it underscores the power of our macrocycle platform as a drug discovery platform and its potential to generate products that can address significant unmet medical needs. From a corporate strategy perspective, this transaction is part of Spexis’ efforts to partner or divest non-core programs and assets as the company works towards exiting its moratorium status and will generate funds and streamline focus which we can utilize towards advancing our core programs in rare disease and oncology. ” About multidrug-resistant Gram-negative bacteria Infections by multidrug-resistant Gram-negative bacteria (GNB) are a major challenge for healthcare professionals. Due to an additional outer cell membrane compared to Gram-positive bacteria, it is more difficult for antibiotics to get into the cell. In addition, this outer membrane carries lipopolysaccharides/endotoxins which induce inflammation and play an important amplifying role in the pathogenesis of infections by GNB and are therefore considered an important virulence factor. Moreover, GNB can acquire resistance to several classes of antibiotics such as carbapenems, fluoroquinolones, tetracyclines and earlier-generation cephalosporins, making infections with GNBs particularly difficult to treat. In 2017, the World Health Organization published a list of 12 classes of priority bacterial pathogens that pose the greatest threat to human health, of which nine classes are Gram-negative.3 About Spexis Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com. About Spexis’ Macrocycle Platforms Spexis possesses what we regard as some of the most distinct, highly diverse and very well characterized macrocycle libraries in the world, together with deep data on same, developed over the course of more than 25 years of research and development and significant investment. These include PEMFinder™, which is comprised of peptidomimetic macrocycles, and MACROFinder™, which are small molecule macrocycles. Each have distinct applications depending on the targets in question, which can be both extracelluar and intracellular targets. In addition to generating the specific OMPTA candidates described in this press release, these platforms have generated multiple other drug candidates in the Spexis pipeline, including murepavidin, balixafortide, lonodelestat and others. For further information please contact: For Investors: Stephen Jasper Managing Director Gilmartin Group stephen@gilmartinir.com For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 9256 feldhaus@feldhaus-partner.ch Disclaimer This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release can be downloaded from www.spexisbio.com References M. Schuster, E. Brabet, K. K. Oi et al. Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae. Science Advances 2023 (9), eadg3683 Research reported in this press release is supported by CARB-X. CARB-X’s funding for this project is provided in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority under agreement number 75A50122C00028; and by awards from Wellcome (WT224842), and Germany’s Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (Accessed: January 11th, 2024) Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 8, 2024 Allschwil, Switzerland, February 8, 2024 Spexis announces closing of sale of preclinical antibiotics program to Basilea Spexis announces closing of sale of preclinical antibiotics program to Basilea Basilea to pay up to CHF 2 million for a preclinical program with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains Transaction is part of Spexis’ efforts to partner or divest non-core programs and assets as the company works through its moratorium status Transaction was subject to certain closing conditions, which now have been met and which will commence payments from Basilea to Spexis Basilea to pay up to CHF 2 million for a preclinical program with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains Basilea to pay up to CHF 2 million for a preclinical program with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains Transaction is part of Spexis’ efforts to partner or divest non-core programs and assets as the company works through its moratorium status Transaction is part of Spexis’ efforts to partner or divest non-core programs and assets as the company works through its moratorium status Transaction was subject to certain closing conditions, which now have been met and which will commence payments from Basilea to Spexis Transaction was subject to certain closing conditions, which now have been met and which will commence payments from Basilea to Spexis Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that it has closed its asset purchase agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) wherein Basilea has now formally become the owner of a preclinical program of antibiotics developed by Spexis from a novel class targeting Gram-negative bacteria, including multidrug-resistant strains.1 The transaction was subject to the approval by the Western District Court of the Canton Basel-Landschaft, which has now been obtained. 1 As part of the completed transaction, Basilea has acquired all program compounds, including intellectual property, and is paying Spexis up to a total of CHF 2 million, which consists of an upfront payment which was now received at closing, a payment related to the near-term transfer of the assets to Basilea, which is expected by the end of February and a potential final milestone payment related to the availability of near-term external funding for the further development of the program. In addition, Basilea has assumed the rights and obligations of Spexis related to the program, including potential low single-digit percentage royalties on sales, under licensing agreements. The assets sold to Basilea are macrocyclic antibiotics developed within Spexis’ Outer Membrane Protein Targeting Antibiotics (OMPTA) program which selectively disrupt the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. This results in a loss of the integrity of the outer cell membrane, intracellular accumulation of lipopolysaccharides and killing of the bacteria. Activity has been shown in vitro and in vivo against Enterobacteriaceae such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy. The program was funded in part by CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)2, a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. Jeff Wager, MD, Chairman & CEO of Spexis, said: “We are very pleased to have finalized this transaction with Basilea as it underscores the power of our macrocycle platform as a drug discovery platform and its potential to generate products that can address significant unmet medical needs. From a corporate strategy perspective, this transaction is part of Spexis’ efforts to partner or divest non-core programs and assets as the company works towards exiting its moratorium status and will generate funds and streamline focus which we can utilize towards advancing our core programs in rare disease and oncology. ” in vitro in vivo Enterobacteriaceae E. coli K. pneumoniae 2 About multidrug-resistant Gram-negative bacteria About multidrug-resistant Gram-negative bacteria Infections by multidrug-resistant Gram-negative bacteria (GNB) are a major challenge for healthcare professionals. Due to an additional outer cell membrane compared to Gram-positive bacteria, it is more difficult for antibiotics to get into the cell. In addition, this outer membrane carries lipopolysaccharides/endotoxins which induce inflammation and play an important amplifying role in the pathogenesis of infections by GNB and are therefore considered an important virulence factor. Moreover, GNB can acquire resistance to several classes of antibiotics such as carbapenems, fluoroquinolones, tetracyclines and earlier-generation cephalosporins, making infections with GNBs particularly difficult to treat. In 2017, the World Health Organization published a list of 12 classes of priority bacterial pathogens that pose the greatest threat to human health, of which nine classes are Gram-negative.3 3 About Spexis About Spexis Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com. www.spexisbio.com About Spexis’ Macrocycle Platforms About Spexis’ Macrocycle Platforms Spexis possesses what we regard as some of the most distinct, highly diverse and very well characterized macrocycle libraries in the world, together with deep data on same, developed over the course of more than 25 years of research and development and significant investment. These include PEMFinder™, which is comprised of peptidomimetic macrocycles, and MACROFinder™, which are small molecule macrocycles. Each have distinct applications depending on the targets in question, which can be both extracelluar and intracellular targets. In addition to generating the specific OMPTA candidates described in this press release, these platforms have generated multiple other drug candidates in the Spexis pipeline, including murepavidin, balixafortide, lonodelestat and others. For further information please contact: For further information please contact: For further information please contact: For Investors: Stephen Jasper Managing Director Gilmartin Group stephen@gilmartinir.com For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 9256 feldhaus@feldhaus-partner.ch For Investors: Stephen Jasper Managing Director Gilmartin Group stephen@gilmartinir.com For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 9256 feldhaus@feldhaus-partner.ch For Investors: Stephen Jasper Managing Director Gilmartin Group stephen@gilmartinir.com For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 9256 feldhaus@feldhaus-partner.ch For Investors: Stephen Jasper Managing Director Gilmartin Group stephen@gilmartinir.com For Investors: For Investors: stephen@gilmartinir.com For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 9256 feldhaus@feldhaus-partner.ch For Media: For Media: feldhaus@feldhaus-partner.ch Disclaimer Disclaimer This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release can be downloaded from www.spexisbio.com www.spexisbio.com References References M. Schuster, E. Brabet, K. K. Oi et al. Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae. Science Advances 2023 (9), eadg3683 Research reported in this press release is supported by CARB-X. CARB-X’s funding for this project is provided in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority under agreement number 75A50122C00028; and by awards from Wellcome (WT224842), and Germany’s Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (Accessed: January 11th, 2024) M. Schuster, E. Brabet, K. K. Oi et al. Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae. Science Advances 2023 (9), eadg3683 Research reported in this press release is supported by CARB-X. CARB-X’s funding for this project is provided in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority under agreement number 75A50122C00028; and by awards from Wellcome (WT224842), and Germany’s Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (Accessed: January 11th, 2024) Language:EnglishCompany:Spexis AGHegenheimermattweg 1254123 AllschwilSwitzerlandPhone:+41 61 567 1600Fax:+41 61 567 1601E-mail:info@spexisbio.comInternet:www.spexisbio.comISIN:CH0106213793Valor:SPEXListed:SIX Swiss ExchangeEQS News ID:1832895 Language:EnglishCompany:Spexis AGHegenheimermattweg 1254123 AllschwilSwitzerlandPhone:+41 61 567 1600Fax:+41 61 567 1601E-mail:info@spexisbio.comInternet:www.spexisbio.comISIN:CH0106213793Valor:SPEXListed:SIX Swiss ExchangeEQS News ID:1832895 Language:English Language: English Company:Spexis AG Company: Spexis AG Hegenheimermattweg 125 Hegenheimermattweg 125 4123 Allschwil 4123 Allschwil Switzerland Switzerland Phone:+41 61 567 1600 Phone: +41 61 567 1600 Fax:+41 61 567 1601 Fax: +41 61 567 1601 E-mail:info@spexisbio.com E-mail: info@spexisbio.com Internet:www.spexisbio.com Internet: www.spexisbio.com ISIN:CH0106213793 ISIN: CH0106213793 Valor:SPEX Valor: SPEX Listed:SIX Swiss Exchange Listed: SIX Swiss Exchange EQS News ID:1832895 EQS News ID: 1832895 End of AnnouncementEQS News Service End of AnnouncementEQS News Service End of AnnouncementEQS News Service End of Announcement EQS News Service